What Famenita Treats: Main Uses and Benefits

Famenita (micronized progesterone) is generally used across several therapeutic domains to manage symptoms related to systemic imbalance and to provide essential support for reproductive health. It is applied in clinical settings where additional management of discomfort is required to restore physiological balance and ease symptomatic burden. Progesterone is prescribed alongside estrogen therapy to manage menopausal symptoms and to produce a period in women who have amenorrhea.

---

Therapeutic Focus and Relief

Famenita is used for managing symptom clusters that may become more noticeable due to hormonal fluctuations, particularly in the menopausal transition. It is relevant for easing symptoms such as frequent hot flashes, interruptive night sweats, and related sleep disturbances. In specific therapeutic contexts, it is applied to address conditions characterized by a lack of sufficient progesterone, including certain forms of secondary amenorrhea, dysfunctional uterine bleeding, and to provide intensive luteal phase support in Assisted Reproductive Technology (ART) protocols. This provides supportive relief that assists with maintaining functional stability.

Clinical Applications

In Hormone Replacement Therapy (HRT) for patients with an intact uterus, Famenita is commonly used to manage the growth of the uterine lining associated with concurrent estrogen use, and may be part of symptomatic management.

Quick Fact: Support for Menopausal Symptoms and Reproductive Cycle Irregularities
This use assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. MedlinePlus Drug Information

Who Can and Cannot Use Famenita?

The population eligibility for Famenita (micronized progesterone) is strictly defined by government regulatory agencies, outlining groups for whom use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations

Famenita is contraindicated and must not be used by patients with specific pre-existing conditions as listed in official labeling. These include a known history of or active venous thromboembolic disease (such as DVT or PE) or arterial thromboembolic disease. Use is also prohibited for patients with known or suspected hormone-sensitive malignancies (like breast carcinoma), severe hepatic dysfunction or active liver disease, and a confirmed missed abortion. Known hypersensitivity to progesterone or excipients, including peanut oil or soya lecithin, also constitutes a contraindication.

Restricted and Limited Use

Certain populations require caution or close medical supervision. Patients with conditions potentially aggravated by fluid retention (e.g., cardiac disease, renal disease, hypertension) must be closely monitored. Caution is also advised for those with a history of epilepsy, migraines, or depression.

Age and Reproductive Status

Use is not established in the pediatric population, and the drug is not indicated for children. While pregnancy is a contraindication for the Hormone Replacement Therapy (HRT) indication, use is permitted for luteal phase support in early pregnancy following Assisted Reproductive Technology (ART) protocols. The medicine is not recommended during lactation.

Interactions with other medicines and products

Famenita, which contains progesterone, is metabolized in the liver, primarily by the cytochrome P450 enzyme system, specifically CYP3A4. This metabolic pathway makes Famenita susceptible to clinically significant drug-drug interactions with other medicinal products.

Medications that affect Famenita levels

• Enzyme Inducers: Strong inducers of hepatic enzymes, such as certain antiepileptic medicines (phenytoin, carbamazepine, phenobarbital), medicines for tuberculosis (rifampicin), and the herbal product St. John's wort (Hypericum perforatum), can increase the metabolism of Famenita. This may lead to a reduction in progesterone plasma levels and a loss of its intended therapeutic effect.
• Enzyme Inhibitors: Medicines that inhibit CYP3A4, such as certain antifungal agents (itraconazole) or HIV protease inhibitors (ritonavir), may increase Famenita plasma levels, potentially leading to an increase in adverse effects.

Famenita's effect on other medicines

Famenita can also affect the clearance of other drugs. For instance, progesterone has been shown to reduce the plasma concentration of lamotrigine (an antiepileptic drug) by accelerating its metabolism, which may result in a loss of seizure control. Conversely, progesterone may potentiate the effects of certain medicines that act on the central nervous system, such as benzodiazepines.

Combination constraints

Concomitant use of Famenita with enzyme-inducing products requires caution, and a non-hormonal barrier method is generally advised if Famenita is being used for a hormonal purpose, continuing for 28 days after stopping the inducer. Combination with other progesterone receptor modulators should be avoided due to the potential for opposing therapeutic effects.

Famenita contains progesterone, a steroidal hormone that functions as a non-selective agonist at the intracellular progesterone receptors (PR). These receptors belong to the nuclear receptor superfamily and exist primarily as two isoforms, PR-A and PR-B.

The classical, genomic mechanism involves progesterone binding to the cytoplasmic PR, causing the receptor to dissociate from its chaperone complex, dimerize, and translocate to the cell nucleus. The liganded dimer binds to Progesterone Response Elements (PREs) within the promoter regions of target genes, recruiting coactivator proteins to modulate gene transcription. This process regulates the synthesis of specific proteins over hours to days. PR-A and PR-B modulate distinct and overlapping sets of genes.

Simultaneously, progesterone engages in rapid, non-genomic actions via membrane-associated progesterone receptors (mPRs) and other membrane-binding proteins. This initiates intracellular signaling cascades, including the activation of mitogen-activated protein kinases (MAPK) pathways and modulation of ion channels, which can occur within minutes. These molecular actions culminate in system-level physiological modulation, including the conversion of proliferative endometrium into secretory endometrium, a decrease in uterine smooth muscle contractility (tocolysis), and inhibition of pituitary gonadotropin release, particularly Luteinizing Hormone (LH).

How Famenita is Used

Famenita, which contains micronized progesterone, is administered according to specific, officially labeled patterns. The medicine is available in 100 mg and 200 mg soft gelatin capsules and is approved for both the oral and vaginal routes of administration. The choice of route and dose is based on the particular use-pattern defined for the medication.

---

Official Administration and Scheduling

The pattern of administration is either cyclic or continuous.

For regimens requiring oral administration, such as for the management of the uterine lining during Hormone Replacement Therapy (HRT) or for the induction of a period in secondary amenorrhea, a typical dose ranges from 200 mg to 400 mg daily. Oral administration is governed by a key time-relationship concept: the capsule must be taken as a single dose at bedtime and without food (on an empty stomach). This condition is critical to maintaining the prescribed absorption profile. Oral capsules must be swallowed whole with water and must not be crushed or chewed.

Treatment duration is typically cyclical for HRT, involving 12 consecutive days of administration per month. For sustained support regimens, such as in luteal phase protocols, the medicine may be administered continuously, often via the vaginal route. Prescribing information states that the medicine is not recommended for use in pediatric patients.

Research Evidence / Overview of Studies for Famenita

This overview summarizes the types of research and general findings described in authoritative sources concerning the clinical evaluation of micronized progesterone (Famenita). It remains a descriptive summary of the research landscape and does not offer clinical advice or guidance.

---

Evidence for Endometrial Protection in Postmenopausal Women

Research examining the use of micronized progesterone for postmenopausal women with an intact uterus has relied on large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used to explore how different regimens of the medicine behave when taken alongside estrogen therapy, primarily to address the assessment of the uterine lining changes associated with concurrent estrogen use.

In these contexts, researchers examined outcomes related to endometrial histology, monitoring the rates of excessive cell growth (hyperplasia) and observing the development of the uterine lining over time. The findings describe patterns observed in these studies where the specific oral regimens were associated with the measured progestational effect on the endometrium.

What remains uncertain is the evidence consistency for all studied routes of administration. The data for vaginal administration regarding providing the measured progestational effect when used in combination with higher estrogen doses remain limited and less consistent across the regulatory record.

---

Evidence for Support During Assisted Reproductive Technology (ART)

The research base for the use of micronized progesterone for Luteal Phase Support (LPS) in procedures like in vitro fertilization (IVF) is well-documented, relying heavily on numerous Randomized Controlled Trials (RCTs) and subsequent Meta-analyses. These studies were conducted during periods of temporary physiological imbalance in women undergoing ART cycles.

The studies explored outcomes related to clinical success, primarily measuring the Live Birth Rate (LBR) and Clinical Pregnancy Rate (CPR). Research describes that the administration of progesterone was observed in some studies to be associated with patterns of difference in pregnancy and live birth rates when compared to control groups or placebo.

What remains uncertain are the ideal protocols for all situations. There is still considerable heterogeneity in the study designs, and the optimal dose, specific timing, and exact duration for all patient subgroups within ART protocols remain an area of ongoing scientific discussion.

---

Evidence Gaps and Areas of Scientific Uncertainty

The scientific literature and regulatory summaries highlight several areas where evidence is not yet conclusive:

• Comparative Evidence: Direct clinical comparisons of micronized progesterone against many synthetic progestins are lacking in the randomized trial data for many non-endometrial outcomes.
• Long-Term Data: For uses outside of long-term HRT for endometrial protection, follow-up durations were limited, meaning data for long-term outcomes and durability of response are not fully established.

Key Studies & References

1. Australian Public Assessment Report for Progesterone (Prometrium/Utrogestan) - Therapeutic Goods Administration (TGA) (Covers Endometrial Protection and ART Indications)
2. The impact of micronized progesterone on the endometrium: a systematic review

Common questions about Famenita (FAQ)

---

Q: Can I take this medication with food?

A: According to the official product information, Famenita can be taken with or without food. The full details regarding administration are typically found in the official product labeling section on 'Posology and method of administration'.

---

Q: Does this medicine interact with other prescription drugs or over-the-counter supplements?

A: The official regulatory documents contain a list of known drug-drug interactions. These are specific medicines or supplements that may change how Famenita works or increase the chance of side effects. The full list and details are provided in the official 'Interactions with other medicinal products and other forms of interaction' section of the label.

---

Q: Is it safe to take this drug long-term?

A: Official regulatory documents indicate conditions for use, which may include a specified maximum recommended duration of use. Warnings and precautions related to prolonged use are detailed in the official product labeling, alongside risks observed in clinical studies.

---

Q: Will this drug make me feel sleepy or affect my ability to drive?

A: Official information indicates that sleepiness (somnolence) and other effects on the nervous system are potential adverse reactions. Caution is advised regarding operating heavy machinery or driving until the effects of the medication are known.

---

Q: What is the recommended dose for children who are 2 years old?

A: Official product information indicates the minimum age for which the medication is approved and its safety has been established. If a population, such as 2-year-old children, is not covered by the approval, the document will state that the safety and effectiveness have not been established in that specific age group.

---

Q: Should I avoid alcohol while taking this medicine?

A: The official warnings section provides specific instructions regarding alcohol consumption. This is typically to prevent additive effects, where the combination could increase the risk of certain side effects. Reviewing the official product information is key to understanding any specific restrictions on alcohol use.

How to Store and Dispose of Famenita?

Famenita (progesterone) capsules must be stored according to official regulatory requirements to maintain product quality and safety.

---

Storage Conditions

Famenita must be kept at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine requires protection from light, moisture, and excess heat, and must be kept from freezing. Store the capsules in the original container and keep it tightly closed at all times.

Child Safety

It is mandatory to store Famenita out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Instructions

Do not dispose of unused or expired Famenita in household trash or wastewater unless specifically instructed. The preferred method is to return the medicine to a drug take-back program or consult a pharmacist or healthcare professional for guidance on proper disposal according to local regulations.